Literature DB >> 21365268

BRCA1/2 genetic testing uptake and psychosocial outcomes in men.

Kristi D Graves1, Rhoda Gatammah, Beth N Peshkin, Ayelet Krieger, Christy Gell, Heiddis B Valdimarsdottir, Marc D Schwartz.   

Abstract

Few studies have quantitatively evaluated the uptake and outcomes of BRCA1/2 genetic counseling and testing in men. We conducted a prospective longitudinal study to describe and compare uptake of and psychosocial outcomes following BRCA1/2 testing in a sample of men and women at high-risk for carrying a BRCA1/2 mutation. Men (n = 98) and women (n = 243) unaffected with cancer completed baseline assessments prior to genetic counseling and testing and then 6- and 12-months post-testing. Most men (n = 94; 95.9%) opted to have genetic testing, of whom 44 received positive BRCA1/2 genetic test results and 50 received true negative results. Among women, 93.4% had genetic testing, of whom 79 received positive results and 148 received negative results. In multivariate models, male BRCA1/2 carriers reported significantly higher genetic testing distress (6-months: Z = 4.48, P < 0.0001; 12-months: Z = 2.78, P < 0.01) than male non-carriers. After controlling for baseline levels of distress, no statistically significant differences emerged between male and female BRCA1/2 carriers in psychological distress at 12-months post-testing, although absolute differences were evident over time. Predictors of distress related to genetic testing among male carriers at 12-months included higher baseline cancer-specific distress (Z = 4.73, P < 0.0001) and being unmarried (Z = 2.18, P < 0.05). Similarly, baseline cancer-specific distress was independently associated with cancer-specific distress at 6- (Z = 3.66, P < 0.001) and 12-months (Z = 4.44, P < 0.0001) post-testing among male carriers. Clinically, our results suggest that pre-test assessment of distress and creation of educational materials specifically tailored to the needs and concerns of male carriers may be appropriate in this important but understudied high-risk group.

Entities:  

Mesh:

Year:  2011        PMID: 21365268      PMCID: PMC3144746          DOI: 10.1007/s10689-011-9425-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  39 in total

1.  A descriptive study of BRCA1 testing and reactions to disclosure of test results.

Authors:  H T Lynch; S J Lemon; C Durham; S T Tinley; C Connolly; J F Lynch; J Surdam; E Orinion; S Slominski-Caster; P Watson; C Lerman; P Tonin; G Lenoir; O Serova; S Narod
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

2.  Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.

Authors:  Kristi D Graves; Beth N Peshkin; Chanita H Halbert; Tiffani A DeMarco; Claudine Isaacs; Marc D Schwartz
Journal:  Breast Cancer Res Treat       Date:  2006-10-26       Impact factor: 4.872

Review 3.  Men's decision-making about predictive BRCA1/2 testing: the role of family.

Authors:  N Hallowell; A Ardern-Jones; R Eeles; C Foster; A Lucassen; C Moynihan; M Watson
Journal:  J Genet Couns       Date:  2005-06       Impact factor: 2.537

4.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

5.  Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing.

Authors:  G Goelen; A Rigo; M Bonduelle; J De Grève
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

Review 6.  A literature review of the psychological impact of genetic testing on breast cancer patients.

Authors:  Kathryn J Schlich-Bakker; Herman F J ten Kroode; Margreet G E M Ausems
Journal:  Patient Educ Couns       Date:  2005-10-19

7.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

8.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

9.  Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.

Authors:  M Watson; C Foster; R Eeles; D Eccles; S Ashley; R Davidson; J Mackay; P J Morrison; P Hopwood; D G R Evans
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

10.  Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.

Authors:  C Foster; M Watson; R Eeles; D Eccles; S Ashley; R Davidson; J Mackay; P J Morrison; P Hopwood; D G R Evans
Journal:  Br J Cancer       Date:  2007-02-06       Impact factor: 7.640

View more
  12 in total

1.  "Second-Class Status?" Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Alexandra Suttman; Robert Pilarski; Doreen M Agnese; Leigha Senter
Journal:  J Genet Couns       Date:  2018-02-05       Impact factor: 2.537

2.  Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.

Authors:  Karen Hurley; Lisa R Rubin; Allison Werner-Lin; Michal Sagi; Yelena Kemel; Rikki Stern; Aliza Phillips; Ina Cholst; Noah Kauff; Kenneth Offit
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

Review 3.  Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature.

Authors:  Lucia Lombardi; Sonia M Bramanti; Alessandra Babore; Liborio Stuppia; Carmen Trumello; Ivana Antonucci; Alessandra Cavallo
Journal:  Support Care Cancer       Date:  2019-06-15       Impact factor: 3.603

4.  Distress and the parenting dynamic among BRCA1/2 tested mothers and their partners.

Authors:  Darren Mays; Tiffani A DeMarco; George Luta; Beth N Peshkin; Andrea F Patenaude; Katherine A Schneider; Judy E Garber; Kenneth P Tercyak
Journal:  Health Psychol       Date:  2013-06-24       Impact factor: 4.267

5.  Decisional outcomes of maternal disclosure of BRCA1/2 genetic test results to children.

Authors:  Kenneth P Tercyak; Darren Mays; Tiffani A DeMarco; Beth N Peshkin; Heiddis B Valdimarsdottir; Katherine A Schneider; Judy E Garber; Andrea Farkas Patenaude
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07       Impact factor: 4.254

6.  Psychological distress related to BRCA testing in ovarian cancer patients.

Authors:  Merete Bjørnslett; Alv A Dahl; Øystein Sørebø; Anne Dørum
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

7.  Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers.

Authors:  Tuya Pal; Susan Vadaparampil; Jongphil Kim; Yan Xu; Sue Friedman; Steven A Narod; Kelly Metcalfe
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

8.  The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.

Authors:  Beth N Peshkin; Mary Kate Ladd; Claudine Isaacs; Hannah Segal; Aryana Jacobs; Kathryn L Taylor; Kristi D Graves; Suzanne C O'Neill; Marc D Schwartz
Journal:  J Cancer Educ       Date:  2021-02       Impact factor: 2.037

9.  Close ties: an exploratory Colored Eco-Genetic Relationship Map (CEGRM) study of social connections of men in Familial Testicular Cancer (FTC) families.

Authors:  June A Peters; Regina Kenen; Lindsey M Hoskins; Gladys M Glenn; Christian Kratz; Mark H Greene
Journal:  Hered Cancer Clin Pract       Date:  2012-03-01       Impact factor: 2.857

10.  A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice--the ProCaRis study: study protocol.

Authors:  Pia Kirkegaard; Peter Vedsted; Adrian Edwards; Morten Fenger-Grøn; Flemming Bro
Journal:  BMJ Open       Date:  2013-03-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.